A Canadian cannabis producer has adjusted its construction plans for a facility expansion in British Columbia, Canada, in an attempt to prevent disruption to its cash flow.

In an update to investors issued on Monday (October 21), Zenabis Global (TSX:ZENA) confirmed the adjusted timeline for the facility. The new plan will delay the site in reaching full capacity.


According to Andrew Grieve, CEO of Zenabis, the facility will still achieve production of 96,400 kilograms by the end of 2019.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Zenabis will split its remaining Zenabis Langley expansion into two phases: Zenabis Langley — Part 2B and Zenabis Langley — Part 2C.

“While the timeline revision for Zenabis Langley will delay achieving full design capacity at the facility, we expect to have 96,400 kg of capacity licensed and operational by the end of 2019 with approval of the Zenabis Langley – Part 2A amendment,” Grieve said.

Zenabis filed an amendment for the 2A phase of its expansion in September and anticipates it will obtain Health Canada approval this year.

The firm plans to submit its license amendment to the regulator for the 2B section in November, while 2C will have to wait until early 2020.

Zenabis indicated that this decision was made due to market conditions at the moment and as way to lower ramp-up risk.

The marijuana producer has lofty expectations for its facility operations and production in Langley.

“By early in the first quarter of 2020, we expect to have 111,200 kilograms of capacity licensed and operational with the approval of the Zenabis Langley — Part 2B amendment,” Grieve said.

The market did not take kindly to the delay in Monday’s trading session. Shares of Zenabis opened at C$0.68 and then quickly fell by 4.41 percent to C$0.65 as of 10:35 a.m. EDT following the announcement.

On analyst data aggregator TipRanks, Zenabis currently holds a “moderate buy” rating based on two recent reviews of the stock.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less

ADASTRA HOLDINGS LTD. ENGAGES HYBRID FINANCIAL LTD.

Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (“Adastra”, or the “Company”) is pleased to announce that it has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for Adastra and to broaden the Company’s reach within the investment community.

Keep reading... Show less